Huons Secures Therapex’s TRX-211 NSCLC Drug

Therapex, a domestic biotech company, has transferred the technology for TRX-211, a novel non-small cell lung cancer (NSCLC) drug candidate it developed in-house, to Huons.

Huons announced on the 23rd that it had signed a contract to introduce TRX-211, a targeted anticancer candidate for non-small cell lung cancer, NSCLC, developed by Therapex, thereby expanding its research and development pipeline.

Under the contract, the company will lead the clinical development of TRX-211, which is in the preclinical stage, and will hold domestic rights after approval. It also has the option to exercise rights for global distribution in the future.

TRX-211 is an oral tyrosine kinase inhibitor (TKI) targeting epithelial growth factor receptor (EGFR) Exon20 insertion mutation non-small cell lung cancer, NSCLC. Lung cancer is classified as small cell lung cancer when the cancer cells are small and non-small cell lung cancer when they are larger.

Huons introduced TRX-211, anticipating that it could provide a new treatment opportunity for patients with EGFR Exon20 insertion mutation NSCLC, who are in urgent need of therapeutic alternatives.

Therapex CEO Lee Koo said, “TRX-211 is a novel drug candidate that embodies Therapex’s know-how in the EGFR mutation non-small cell lung cancer treatment field. We will present a new model where a technology-based biotech grows into a commercialization entity by actively utilizing Huons’ excellent R&D infrastructure and clinical network.”

Huons CEO Song Soo-young stated, “This is an open innovation model where Huons’ global clinical and commercialization experience is combined with Therapex’s advanced targeted anticancer technology. Going forward, we will create Huons’ unique synergy in novel drug development by actively embracing long-term visions and external technologies.”